Loading…
← CockpitCompetitor Analysis › 041830.KS InBody Co., Ltd.Open in the cockpit ↗

InBody Co., Ltd.041830.KSCompetitor analysis, valuation and peers

South Korea · KRW·Health Care›Medical Specialties
Momentum neutral 42
Mkt cap
$380M
US dollars, full cap
Free float
62%
of shares outstanding
$/day
$3.29M
20-day average traded
Fwd P/E
11.3×
forward earnings
ROIC−WACC
+13.0 pp
WACC 7.3%
Hurdle
-27 pp
Req g minus delivered
Next earnings
99 days
25 Feb 2027
Close · KRW₩40,000
1D+1.8%
1W-2.0%
1M-20.6%
3M-37.9%
6M-13.1%
YTD+22.1%
1Y+47.3%
ATR %8.9%
52w lowhigh45.6% off high

What InBody does

Employees: 370

InBody at a glance

Size InBody (041830.KS) is a South Korea Health Care company (Medical Specialties) with a market value of $380M, the 416th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩40,000 on 18 Nov 2026.

Performance Over six months the shares fell 13.1%, against -18.1% for the median peer and -37.2% for the South Korea market (cap-weighted) — 7th highest of 20 in its peer set.

Growth Revenue grew 21.5% over the last twelve months (peer median +7.1%); the operating margin is 21.6% (peer median 7.9%).

Valuation It trades at 11.3× forward earnings against a peer median of 19.0× (3rd cheapest of 11).

Price implies For today's price to make sense, revenue must grow about -10% a year for seven years (Req g). Recent delivered growth is +17%, so the hurdle is -27 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 13.0 points above its cost of capital (7.3% WACC).

Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012515021 May 202621 Aug 202618 Nov 2026041830.KS 89Peer median 83
Six months, rebased to 100: InBody against the median of its 20 peers (local-currency closes).

InBody financials

Reported figures in KRW; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₩275B₩234B₩204B₩170B₩160B
Revenue growth—+14%+20%+6%—
Gross profit₩214B₩174B₩153B₩128B₩117B
EBITDA₩69.1B₩44.7B₩42.7B₩44.3B₩46.1B
Net income₩41.5B₩30.6B₩33.1B₩36.7B₩33.8B
Free cash flow₩37.8B₩28.9B₩22.3B₩31.2B₩25.0B
Capital expenditure₩4.76B₩7.42B₩7.55B₩7.64B₩6.02B
Total debt₩10.6B₩10.3B₩8.42B₩6.08B₩6.40B

Quarterly statements and history in the cockpit →

InBody competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%-40%-20%0%+20%60518667484736300562BWAY4588706929CVMASSSBS1609300238688338041830.KS6-month return →1-month return →
Up and to the right = strong over both horizons. InBody is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%+150%10×20×30×605186300562BWAY4588706929SBS688338688133688358300653041830.KSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. InBody is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%0%100%200%20414736300562BWAY4588706929MASS1609041830.KSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. InBody is the large dot.

InBody competitors and peer comparison

How InBody compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

InBody against its 20 peers (data as of 18 Nov 2026)
Measure041830.KSPeer medianRank in peer set
1-month return-20.6%-10.9%3rd lowest of 21
6-month return-13.1%-18.1%7th highest of 20
Distance from 52-week high-45.6%-43.6%9th lowest of 21
Revenue growth (TTM)+21.5%+7.1%5th highest of 21
Operating margin21.6%7.9%5th highest of 21
Forward P/E11.3×19.0×3rd cheapest of 11
Growth the price implies (Req g, 7 yrs)-10.3%5.7%4th least demanding of 14
Growth delivered (Del g)+16.9%+5.6%5th highest of 14
Hurdle (Req g minus delivered)-27.2 pp+1.8 pp4th least demanding of 14
ROIC minus cost of capital+13.0 pp+4.7 pp6th highest of 20
EV / EBITDA5.4×8.9×2nd cheapest of 10
Net debt / EBITDA-1.9×-3.6×5th most indebted of 10

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
InBody 041830.KSSouth Korea$380M-13%+22%22%11.3×-10.3%+16.9%
Shanghai General Healthy Information & Technology 605186.SSChina$379M-26%-11%5%37.2×n/an/a
Medcaptain Medical Technology 2041.HKHong Kong$378Mn/a+19%2%n/a17.1%+18.1%
ACRO Biomedical 6748.TWOTaiwan$377M+158%+45%-178%n/an/an/a
Taidoc Technology 4736.TWTaiwan$387M0%0%19%n/a-9.5%-6.6%
Guangdong Transtek Medical Electronics 300562.SZChina$373M-15%+7%11%25.3×-4.2%-6.0%
Brainsway Ltd Sponsored ADR BWAYUnited States$373M-41%+32%14%20.3×24.9%+18.8%
Shanghai Kehua Bio-Engineering 002022.SZChina$389M-14%+7%-40%n/an/an/a
Cerus CERSUnited States$392M-28%+14%-12%n/an/an/a
SEERS 458870.KSSouth Korea$392M-70%+174%37%15.2×-6.3%+247.0%
OrbusNeich Medical 6929.HKHong Kong$394M-15%+16%23%8.4×-17.6%+15.4%
CapsoVision CVUnited States$366M+5%+15%-213%n/an/an/a
908 Devices MASSUnited States$396M+36%+14%-33%n/a41.7%+15.9%
Stratec SBS.DEGermany$365M+63%-6%4%18.2×19.1%+0.1%
Star Sports Medicine 1609.HKHong Kong$364M-73%+23%37%n/a-13.1%+36.8%
Guanhao Biotech 300238.SZChina$397M-26%-12%3%n/an/an/a
Beijing Succeeder Technology 688338.SSChina$362M-18%-4%31%16.4×5.7%+3.4%
Shanghai Titan Scientific 688133.SSChina$403M-26%+1%-6%8.4×n/an/a
Chison Medical Technologies 688358.SSChina$406M-27%-1%19%19.8×9.6%+5.6%
Yantai Zhenghai Bio-Tech 300653.SZChina$354M-23%-8%17%36.0×18.4%+4.4%
IVF HARTMANN VBSN.SWSwitzerland$352M-2%+7%14%n/a-12.7%-1.3%

Questions

Which companies are InBody's closest peers?
The cockpit's peer set: Shanghai General Healthy Information & Technology (605186.SS), Medcaptain Medical Technology (2041.HK), ACRO Biomedical (6748.TWO), Taidoc Technology (4736.TW), Guangdong Transtek Medical Electronics (300562.SZ), Brainsway Ltd Sponsored ADR (BWAY), Shanghai Kehua Bio-Engineering (002022.SZ), Cerus (CERS).
Is InBody expensive compared with its peers?
On forward p/e it trades at 11.3× against a peer median of 19.0×, 3rd cheapest of 11 in its peer set. For today's price to make sense, revenue must grow about -10% a year for seven years (Req g). Recent delivered growth is +17%, so the hurdle is -27 pp: the price already allows for a slowdown.
How has InBody stock performed?
Over six months to 18 Nov 2026 the shares returned -13.1% against -18.1% for the median peer; over one year +47.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.